KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on Sales

Amneal Pharmaceuticals (AMRX) Gross Margin (2017 - 2025)

Historic Gross Margin for Amneal Pharmaceuticals (AMRX) over the last 9 years, with Q3 2025 value amounting to 34.92%.

  • Amneal Pharmaceuticals' Gross Margin fell 34500.0% to 34.92% in Q3 2025 from the same period last year, while for Sep 2025 it was 36.76%, marking a year-over-year increase of 14200.0%. This contributed to the annual value of 36.52% for FY2024, which is 22400.0% up from last year.
  • As of Q3 2025, Amneal Pharmaceuticals' Gross Margin stood at 34.92%, which was down 34500.0% from 39.51% recorded in Q2 2025.
  • Amneal Pharmaceuticals' Gross Margin's 5-year high stood at 39.71% during Q2 2021, with a 5-year trough of 30.77% in Q4 2023.
  • Moreover, its 5-year median value for Gross Margin was 35.98% (2024), whereas its average is 35.96%.
  • Its Gross Margin has fluctuated over the past 5 years, first surged by 118300bps in 2021, then crashed by -45600bps in 2023.
  • Over the past 5 years, Amneal Pharmaceuticals' Gross Margin (Quarter) stood at 30.99% in 2021, then grew by 14bps to 35.32% in 2022, then dropped by -13bps to 30.77% in 2023, then increased by 17bps to 35.98% in 2024, then dropped by -3bps to 34.92% in 2025.
  • Its Gross Margin stands at 34.92% for Q3 2025, versus 39.51% for Q2 2025 and 36.8% for Q1 2025.